Trial
NCT06281106
TYK2 Inhibition in Paradoxical Psoriasis
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Prof Curdin Conrad
Collaborators
Centre Hospitalier Universitaire Vaudois
Condition
Psoriasis
Intervention
Deucravacitinib
Why stopped
External research funds were canceled, so study could unforunately not be continued
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-02